+1 (917) 893 7512

  • #
  • #
  • #

US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)

Publish Date:Nov 2016
No. of Pages:54

Format : Adobe Reader (PDF) Instant delivery

US$ 800.00

Scope of the Report

The report entitled “US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)”, provides analysis of the US tardive dyskinesia market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the major drugs (both existing and in pipeline) analysis, by penetrations, by revenue, etc.

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall US tardive dyskinesia market has been forecasted for the years 2016-2025, taking into consideration the previous growth pattern, the growth drivers and the current and future trends.

Valeant Pharmaceuticals, Neurocrine Biosciences and Teva Pharmaceutical Industries are some of the key companies in the US tardive dyskinesia market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.

Company Coverage

Valeant Pharmaceuticals (Tertrabenazine)
Neurocrine Biosciences (Valbenazine)
Teva Pharmaceutical Industries (SD-809)

Executive Summary

Psychosis is a condition described as loss of contact with reality. And the people suffering from this condition are called psychotics. Some of the signs and symptom of psychosis are: difficulty in concentrating, depressed mood, sleeping too much or not enough, anxiety, etc. The two main types of psychiatric disorder related to tardive dyskinesia are Schizophrenia and Bipolar Disorder.

Involuntary movements of face, lips, tongue, extremities and trunk, is called tardive dyskinesia. This disease is caused by regular and long term intake of dopaminergic antagonist medications/ antipsychotics as a prescription for schizophrenia and bipolar disorder. Some of the signs and symptoms of tardive dyskinesia are grimacing, tongue movements, lip smacking, lip puckering, pursing of the lips, excessive eye blinking, etc.

Tardive dyskinesia has many different treatments, including vitamin E, benzodiazepines, levodopa, reserpine, botullinum toxin, tetrabenazine, dopamine-depleting agents, and calcium channel blockers. Along with these, two new treatments are in the pipeline: Valbenazine and SD-809.

The US tardive dyskinesia market is expected to increase at a significant growth rate during the forecasted period (2016-2025). The US tardive dyskinesia market is supported by various growth drivers, such as increase in number of schizophrenia patients, rising bipolar disorder patients, etc. Yet, the market faces certain challenges, such as, increased use of atypical antipsychotics, under-diagnosed market, side effects of drugs, etc.

1. Executive Summary

2. Introduction

2.1 Psychosis: An Overview

2.1.1 Psychosis
2.1.2 Psychotic Disorder
2.1.3 Schizophrenia 
2.1.4 Bipolar Disorder

2.2 Antipsychotics: An Overview
2.3 Tardive Dyskinesia: An Overview

2.3.1 Signs and Symptoms
2.3.2 Causes
2.3.3 Treatment
2.3.4 Existing and Pipeline Drugs

3. US Market Analysis

3.1 US Tardive Dyskinesia Market: An Analysis

3.1.1 US Tardive Dyskinesia Market by Number of Patients
3.1.2 US Tardive Dyskinesia Market Number of Patients by Segments
3.1.3 US Tardive Dyskinesia Market Number of Patients by Severity

3.2 US Tardive Dyskinesia Drugs Market; An Analysis

3.2.1 US Valbenazine Market by Penetration
3.2.2 US Valbenazine Market by Number of Patients
3.2.3 US Valbenazine Market by Price and Revenue
3.2.4 US SD-809 Market by Penetration
3.2.5 US Tetrabenazine Market (For TD) by Penetration

4. Market Dynamics

4.1 Growth Drivers

4.1.1 Increasing Schizophrenia Patients
4.1.2  Rising Bipolar Disorder Patients
4.1.3 Growing Antipsychotics Prescription

4.2 Challenges

4.2.1 Tardive Dyskinesia Prevalence by Drug Class
4.2.2 Side Effects of Drugs
4.2.3 Under-diagnosed

4.3 Market Trends

4.3.1 Medications Causing Tardive Dyskinesia
4.3.2 Diagnosis of Tardive Dyskinesia
5. Competitive Landscape

6. Company Profiling

6.1 Valeant Pharmaceuticals (Tetrabenazine)
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategy

6.2 Neurocrine Biosciences, Inc. (Valbenazine)
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategy

6.3 Teva Pharmaceuticals Industries Ltd. (SD-809)
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategy
Figure 1: Signs and Symptoms of Psychosis
Figure 2: Psychiatric Disorder
Figure 3: Side Effects of Antipsychotics
Figure 4: Signs and Symptoms of Tardive Dyskinesia
Figure 5: US Tardive Dyskinesia Market by Number of Patients; 2016-2020 (‘000)
Figure 6: US Tardive Dyskinesia Market Number of Patients by Segments; 2017
Figure 7: US Tardive Dyskinesia Market Number of Patients by Severity; 2016-2025 (‘000)
Figure 8: US Valbenazine Market by Penetration; 2017-2025
Figure 9: US Valbenazine Market by Number of Patients and Compliance Rate; 2017-2025 
Figure 10: US Valbenazine Market by Price; 2017-2025 US$)
Figure 11: US Valbenazine Market by Revenue; 2017-2025 (US$ Million)
Figure 12: US SD-809 Market by Penetration; 2019-2025 
Figure 13: US Tetrabenazine Market (For TD) by Penetration; 2017-2025 
Figure 14: Schizophrenia Patients  in the USW; 2017-2025 (‘000)
Figure 15: Bipolar Disorder Patients in the US; 2017-2025 (‘000)
Figure 16: Antipsychotic Prescription; Jan13-Sep16 (‘000) 
Figure 17: Tardive Dyskinesia Prevalence by Drug Class 
Figure 18: Valeant Revenue; 2010-2015 (US$ Billion)
Figure 19: Valeant Revenue by Segments; 2015
Figure 20: Neurocrine Revenue; 2011-2015 (US$ Million)
Figure 21: Neurocrine  Research and Development Expense; 2013-2015 (US$ Million)
Figure 22: Teva Revenue; 2011-2015 (US$ Billion)
Figure 23: Teva Revenues by Segment; 2015
Table 1: Medications Causing Tardive Dyskinesia
Table 2: US Tardive Dyskinesia Market Players by Financial Comparison
Table 3: Acquisitions of Valeant Pharmaceuticals